公开(公告)号：US20240158399A1

公开(公告)日：2024-05-16

申请号：US18169361

申请日：2023-02-15

Applicant: Novartis AG

Inventor： Luca ARISTA ,  Christina HEBACH ,  Gregory John HOLLINGWORTH ,  Philipp HOLZER ,  Patricia IMBACH-WEESE ,  Julien LORBER ,  Rainer MACHAUER ,  Niko SCHMIEDEBERG ,  Anna VULPETTI ,  Thomas ZOLLER

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D519/00 ,  A61K45/06

Abstract: The invention relates to compounds of the formula (I)






or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

公开(公告)号：US20230398117A1

公开(公告)日：2023-12-14

申请号：US18060796

申请日：2022-12-01

Applicant: Novartis AG

Inventor： Luca ARISTA ,  Christina HEBACH ,  Gregory John HOLLINGWORTH ,  Philipp HOLZER ,  Patricia IMBACH-WEESE ,  Rainer MACHAUER ,  Niko SCHMIEDEBERG ,  Anna VULPETTI ,  Thomas ZOLLER

IPC: A61K31/519 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

CPC classification number: A61K31/519 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

Abstract: The invention relates to compounds of the formula (I)




or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

公开(公告)号：US20180251432A1

公开(公告)日：2018-09-06

申请号：US15974190

申请日：2018-05-08

Applicant: Novartis AG

Inventor： Daniela ANGST ,  Francois GESSIER ,  Anna VULPETTI

IPC: C07D239/47 ,  A61K31/505 ,  A61P35/02 ,  A61P29/00 ,  A61K31/506 ,  C07D401/12 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12

Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US20250115572A1

公开(公告)日：2025-04-10

申请号：US18729949

申请日：2023-01-20

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Lara C. CZABANIUK ,  Stefanie FLOHR ,  François GESSIER ,  Michael Christoph HEDIGER ,  Konstanze HURTH ,  Nancy LABBE-GIGUERE ,  Fabio LIMA ,  Tajesh PATEL ,  Oliver SIMIC ,  Martin SENDZIK ,  Angela VITREY ,  Anna VULPETTI

IPC: C07D401/06 ,  A61K31/438 ,  A61K31/444 ,  C07D401/14 ,  C07D405/14

Abstract: Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).

公开(公告)号：US20230312483A1

公开(公告)日：2023-10-05

申请号：US18309948

申请日：2023-05-01

Applicant: Novartis AG

Inventor： Daniela ANGST ,  François GESSIER ,  Anna VULPETTI

IPC: C07D239/47 ,  C07D403/12 ,  C07D401/14 ,  C07D401/10 ,  C07D401/12 ,  C07D405/12 ,  A61P29/00 ,  A61P35/02 ,  A61K31/505 ,  A61K31/506

CPC classification number: C07D239/47 ,  C07D403/12 ,  C07D401/14 ,  C07D401/10 ,  C07D401/12 ,  C07D405/12 ,  A61P29/00 ,  A61P35/02 ,  A61K31/505 ,  A61K31/506

Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

公开(公告)号：US20220387602A1

公开(公告)日：2022-12-08

申请号：US17642285

申请日：2020-09-14

Applicant: NOVARTIS AG

Inventor： Luca ARISTA ,  Valerie BROENNIMANN ,  Pier Luca D'ALESSANDRO ,  Lionel DOUMAMPOUOM-METOUL ,  Marie-Line GOUDE ,  Christina HEBACH ,  Gregory John HOLLINGWORTH ,  Ingrid Karen Jennifer JEULIN ,  Louise Clare KIRMAN ,  Julien LORBER ,  Fupeng MA ,  Anna VULPETTI ,  Ken YAMADA ,  Thomas ZOLLER

IPC: A61K47/55 ,  A61K47/54

Abstract: Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

公开(公告)号：US20220315578A1

公开(公告)日：2022-10-06

申请号：US17020114

申请日：2020-09-14

Applicant: NOVARTIS AG

Inventor： Xin CHEN ,  Marie-Line GOUDE ,  Edmund Martin HARRINGTON ,  Gregory John HOLLINGWORTH ,  Julien LORBER ,  Martin SENDZIK ,  Anna VULPETTI ,  Thomas ZOLLER

IPC: C07D471/04 ,  C07D401/14

Abstract: The disclosure provides BRD9 bifunctional compounds of Formula (A), (BF-I), (BF-II), (BF-III), (BF-IIIa), (BF-IIIb), (BF-IV), (BF-IVa), (BF-IVb), (BF-I′), (BF-II′), (BF-III′), (BF-IV′), or (BF-V′), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodomain-containing protein 9 (BRD9).

公开(公告)号：US20220363671A1

公开(公告)日：2022-11-17

申请号：US17642292

申请日：2020-09-16

Applicant: NOVARTIS AG

Inventor： Jake AXFORD ,  Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Nicole BUSCHMANN ,  Artiom CERNIJENKO ,  Janetta DEWHURST ,  Aleem FAZAL ,  Matthew James HESSE ,  Lauren HOLDER ,  Viktor HORNAK ,  Hidetomo IMASE ,  Rama JAIN ,  Xianming JIN ,  John Ryan KERRIGAN ,  Julie LACHAL ,  Fupeng MA ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Daniel MCKAY ,  Robert Joseph MOREAU ,  Pierre NIMSGERN ,  Gary O'BRIEN ,  Anna VULPETTI ,  Ken YAMADA ,  Junping ZHAO

IPC: C07D405/04 ,  A61K31/513 ,  C07D471/04 ,  C07D413/04 ,  C07D401/14

Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.